comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-06 04:40:59 - browse：3896

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Data show record exodus of life scientists from academia

WSS

Group opposing PBM reform sets lobbying record

A public scorecard can help hold safety

Researchers use wearables data and AI to predict preterm birth risk

Startup Neumora takes a novel depression drug to Phase 3

Paxlovid should be available without a positive Covid test

FDA approves RSV monoclonal antibody for infants, toddlers

focus

comprehensive

hotspot

Affirmative action in medical school literally saved lives

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Psychedelics group wrestles with new pharma identity

Inequities make cancer less preventable for women: report

ChatGPT in medicine: STAT answers readers' burning questions

FDA seeks to regulate lab

Hepatitis C has a cure — but many Americans still lack access to it

Address the ethical violations that led to 'Three Identical Strangers'

DIEP, the 'gold standard' of breast reconstruction, is under threat

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

entertainment

How one patient went off dialysis — and others can too

Covid vaccines: Private market messier than government rollout

Sanders adds drug shortage policies to pandemic preparedness bill

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

In early work, researchers turn to CRISPR to treat Alzheimer's

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

leisure time

hotspot

focus

leisure time